文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

基于生物学异质性的重型COVID-19呼吸衰竭新亚型:一项随机对照试验的二次分析

Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trial.
PubMed 文献 · Crit Care · 2024-02-21
一句话结论在需要≥6 L/min补氧的重型COVID-19患者中识别出两种生物学亚型,亚型2(占27%)炎症、内皮与上皮损伤及凝血紊乱持续存在,死亡率约为亚型1的两倍。

该研究为多机构平台随机对照试验(I-SPY COVID)的二次分析,纳入2020年9月至2021年10月入组的400例需要≥6 L/min补氧的重型COVID-19成人患者,入组时检测17种预设血浆蛋白生物标志物。采用潜类别分析识别出两种亚型:亚型2占27%,以炎症、内皮与上皮损伤标志物及凝血紊乱持续存在为特征,死亡率约为亚型1的两倍。用既往验证的非COVID ARDS模型(IL-8、碳酸氢盐、蛋白C)分类时仅1人符合高炎症型。作者认为生物学异质性可能解释COVID-19住院患者试验结果不一致,并可指导治疗策略。

要点

  • 400例需≥6 L/min补氧的重型COVID-19患者中识别出两种生物学亚型,亚型2占27%,死亡率约为亚型1的两倍。
  • 亚型2的特征为炎症、内皮与上皮损伤标志物及凝血紊乱持续存在。
  • IL-6、IL-8、IL-10、sTNFR-1、TREM-1、sRAGE、Ang-1、血栓调节蛋白与28天和60天死亡率相关。
  • 用既往验证的非COVID ARDS高/低炎症模型分类时,仅1人被判为高炎症型,提示COVID-19亚型不同于非COVID ARDS亚型。
  • 入组时85%需要高流量氧疗或无创通气,97%正在接受地塞米松治疗。

适用人群与场景

  • 多机构平台随机对照试验(I-SPY COVID)中2020年9月至2021年10月入组的400例成人重型COVID-19低氧性呼吸衰竭患者,需≥6 L/min补充氧。
  • 入组时平均年龄60±14岁,67%为男性,85%需要高流量氧疗或无创通气,97%正在接受地塞米松。

诊断标准与关键阈值

  • 采用潜类别分析(LCA)基于临床变量和17种预设血浆蛋白生物标志物识别亚型。
  • 亚型2(占27%)的特征为炎症、内皮与上皮损伤标志物及凝血紊乱持续存在。
  • 采用既往验证的简约模型(IL-8、碳酸氢盐、蛋白C)进行分类时,仅1人被判为高炎症型。

研究设计与关键结果

  • 研究类型:多机构平台随机对照试验(I-SPY COVID)的二次分析;样本量400例;人群为需≥6 L/min补氧的成人重型COVID-19低氧性呼吸衰竭患者;入组时间2020年9月至2021年10月。
  • 28天死亡率为25%。
  • 炎症标志物(IL-6、IL-8、IL-10、sTNFR-1、TREM-1)、上皮损伤标志物(sRAGE)和内皮损伤标志物(Ang-1、血栓调节蛋白)与28天和60天死亡率相关。
  • 识别出两种潜亚型;亚型2占27%,死亡率约为亚型1的两倍。
  • 用既往验证的非COVID ARDS高/低炎症模型分类时,仅1人被判为高炎症型。

证据类型、等级与局限

  • 证据类型:多机构平台随机对照试验的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为生物学异质性可能解释COVID-19住院患者试验结果不一致,并可指导治疗策略。
  • 作者认为两种新亚型与既往非COVID ARDS高/低炎症亚型不同,提示不能直接套用非COVID ARDS的亚型分类。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Despite evidence associating inflammatory biomarkers with worse outcomes in hospitalized adults with COVID-19, trials of immunomodulatory therapies have met with mixed results, likely due in part to biological heterogeneity of participants. Latent class analysis (LCA) of clinical and protein biomarker data has identified two subtypes of non-COVID acute respiratory distress syndrome (ARDS) with different clinical outcomes and treatment responses. We studied biological heterogeneity and clinical outcomes in a multi-institutional platform randomized controlled trial of adults with severe COVID-19 hypoxemic respiratory failure (I-SPY COVID).

METHODS: Clinical and plasma protein biomarker data were analyzed from 400 trial participants enrolled from September 2020 until October 2021 with severe COVID-19 requiring ≥ 6 L/min supplemental oxygen. Seventeen hypothesis-directed protein biomarkers were measured at enrollment using multiplex Luminex panels or single analyte enzyme linked immunoassay methods (ELISA). Biomarkers and clinical variables were used to test for latent subtypes and longitudinal biomarker changes by subtype were explored. A validated parsimonious model using interleukin-8, bicarbonate, and protein C was used for comparison with non-COVID hyper- and hypo-inflammatory ARDS subtypes.

RESULTS: Average participant age was 60 ± 14 years; 67% were male, and 28-day mortality was 25%. At trial enrollment, 85% of participants required high flow oxygen or non-invasive ventilation, and 97% were receiving dexamethasone. Several biomarkers of inflammation (IL-6, IL-8, IL-10, sTNFR-1, TREM-1), epithelial injury (sRAGE), and endothelial injury (Ang-1, thrombomodulin) were associated with 28- and 60-day mortality. Two latent subtypes were identified. Subtype 2 (27% of participants) was characterized by persistent derangements in biomarkers of inflammation, endothelial and epithelial injury, and disordered coagulation and had twice the mortality rate compared with Subtype 1. Only one person was classified as hyper-inflammatory using the previously validated non-COVID ARDS model.

CONCLUSIONS: We discovered evidence of two novel biological subtypes of severe COVID-19 with significantly different clinical outcomes. These subtypes differed from previously established hyper- and hypo-inflammatory non-COVID subtypes of ARDS. Biological heterogeneity may explain inconsistent findings from trials of hospitalized patients with COVID-19 and guide treatment approaches.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Alipanah-Lechner N, Hurst-Hopf J, Delucchi K, et al. Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trial. Crit Care. 2024. PMID: 38383504. doi:10.1186/s13054-024-04819-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。